Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (121-130 of 297) with videos related to

Pageof 30
Sort By:
Cancer Immunology, Immunotherapy : CII|August 29, 2014
Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junctionMarie-Cristine Kuehnle, Sebastian Attig, Cedrik M Britten, et al.
Clinical Lung Cancer|July 5, 2014
Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patientsDaniel C Christoph, Bernadette Reyna-Asuncion, Biftu Hassan, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2024
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapiesGregor Zaun, Sabrina Borchert, Martin Metzenmacher, et al.
Endocrine-Related Cancer|September 2, 2021
Antitumor immune response is associated with favorable survival in GEP-NEN G3Vivian Rosery, Henning Reis, Konstantinos Savvatakis, et al.
Journal of Cachexia, Sarcopenia and Muscle|August 6, 2025
Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival PrognosisMarc-David Künnemann, Christian Römer, Anne Helfen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsJames Chih-Hsin Yang, Vera Hirsh, Martin Schuler, et al.
Clinical EEG and Neuroscience|October 21, 2024
Neurofeedback Reduces P300 Amplitudes to Intensely Emotive Pictures in Depressed Cancer PatientsMarvin Krawutschke, Martin Teufel, Kira Schmidt, et al.
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvantJohanna E A Portielje, Wim H J Kruit, Anke J M Eerenberg, et al.
Scientific Reports|June 14, 2024
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapyCedric Richlitzki, Marcel Wiesweg, Martin Metzenmacher, et al.
Oncology Research and Treatment|January 9, 2023
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)Isabel Virchow, Jürgen-Walter Treckmann, Nicole Prasnikar, et al.
Pageof 30

Showing results (121-130 of 297) with videos related to

Sort By:
Pageof 30
Cancer Immunology, Immunotherapy : CII|August 29, 2014
Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junctionMarie-Cristine Kuehnle, Sebastian Attig, Cedrik M Britten, et al.
Clinical Lung Cancer|July 5, 2014
Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patientsDaniel C Christoph, Bernadette Reyna-Asuncion, Biftu Hassan, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2024
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapiesGregor Zaun, Sabrina Borchert, Martin Metzenmacher, et al.
Endocrine-Related Cancer|September 2, 2021
Antitumor immune response is associated with favorable survival in GEP-NEN G3Vivian Rosery, Henning Reis, Konstantinos Savvatakis, et al.
Journal of Cachexia, Sarcopenia and Muscle|August 6, 2025
Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival PrognosisMarc-David Künnemann, Christian Römer, Anne Helfen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsJames Chih-Hsin Yang, Vera Hirsh, Martin Schuler, et al.
Clinical EEG and Neuroscience|October 21, 2024
Neurofeedback Reduces P300 Amplitudes to Intensely Emotive Pictures in Depressed Cancer PatientsMarvin Krawutschke, Martin Teufel, Kira Schmidt, et al.
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvantJohanna E A Portielje, Wim H J Kruit, Anke J M Eerenberg, et al.
Scientific Reports|June 14, 2024
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapyCedric Richlitzki, Marcel Wiesweg, Martin Metzenmacher, et al.
Oncology Research and Treatment|January 9, 2023
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)Isabel Virchow, Jürgen-Walter Treckmann, Nicole Prasnikar, et al.
Pageof 30